# Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS

> **NCT04717908** · NA · COMPLETED · sponsor: **Huashan Hospital** · enrollment: 89 (actual)

## Conditions studied

- Multidrug Resistant Tuberculosis

## Interventions

- **DRUG:** Bedaquiline
- **DRUG:** Pyrazinamide
- **DRUG:** Linezolid
- **DRUG:** Cycloserine
- **DRUG:** Clofazimine

## Key facts

- **NCT ID:** NCT04717908
- **Lead sponsor:** Huashan Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-20
- **Primary completion:** 2024-06-22
- **Final completion:** 2024-06-22
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2024-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04717908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04717908, "Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04717908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*